Literature DB >> 22459106

Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens-Johnson syndrome.

Siddharth Kesarwani1, Srikant Kumar Sahu, Soumyava Basu.   

Abstract

Bevacizumab is widely used for several ocular conditions, including age-related macular degeneration, diabetic retinopathy, corneal neovascularization, neovascular glaucoma, and retinopathy of prematurity. We describe a 14-year-old patient with Stevens-Johnson syndrome in whom subconjunctival injection of bevacizumab in one eye caused bilateral regression of corneal neovascularization.
Copyright © 2012 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22459106     DOI： 10.1016/j.jaapos.2011.12.153

Source DB:  PubMed          Journal:  J AAPOS        ISSN： 1091-8531            Impact factor:   1.220


  5 in total

1.  Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report.

Authors:  Ludovico Iannetti; Alessandro Abbouda; Claudia Fabiani; Roberta Zito; Michelangelo Campanella
Journal:  J Med Case Rep       Date:  2013-07-26

2.  Propranolol eye drops in patients with corneal neovascularization.

Authors:  Luca Filippi; Cinzia de Libero; Barbara Zamma Gallarati; Pina Fortunato; Elena Piozzi
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

3.  Opportunities and challenges for successful use of bevacizumab in pediatrics.

Authors:  Amy Barone; Joshua B Rubin
Journal:  Front Oncol       Date:  2013-04-29       Impact factor: 6.244

Review 4.  Changing paradigms of anti-VEGF in the Indian scenario.

Authors:  P Mahesh Shanmugam
Journal:  Indian J Ophthalmol       Date:  2014-01       Impact factor: 1.848

5.  Simultaneous Subconjunctival Triamcinolone and Bevacizumab Injections for Management of Blepharokeratoconjunctivitis in Children.

Authors:  Chu Luan Nguyen; Tony S Chen; Khoi Tran; James E H Smith; Noni Lewis
Journal:  Case Rep Ophthalmol Med       Date:  2018-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.